1. Exploring the role of MIA-602 in overcoming Doxorubicin-resistance in acute myeloid leukemia.
- Subjects
ACUTE myeloid leukemia ,MEDICAL sciences ,MYELOID leukemia ,MEDICAL research - Abstract
A research paper titled "Exploring the role of GHRH antagonist MIA-602 in overcoming Doxorubicin-resistance in acute myeloid leukemia" was recently published in Oncotarget's Volume 15. The paper investigates the potential of the growth hormone-releasing hormone (GHRH) receptor antagonist MIA-602 as a treatment for Doxorubicin-resistant acute myeloid leukemia (AML). The study found that MIA-602 significantly reduced cell viability in both wild-type AML cells and Doxorubicin-resistant clones. In an in vivo experiment using xenografted mice, MIA-602 treatment resulted in a reduction in tumor volume compared to the control group. The researchers suggest that GHRH antagonists like MIA-602 may offer an alternative treatment approach for AML and drug-resistant AML, potentially avoiding the side effects associated with standard chemotherapy. [Extracted from the article]
- Published
- 2024